Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raquel Hontecillas

Showing results (41-50 of 124) with videos related to

Pageof 13
Sort By:
Journal of Molecular Modeling|June 1, 2010
Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeuticsPinyi Lu, David R Bevan, Stephanie N Lewis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2024
Immunometabolic Mechanisms of LANCL2 in CD4+ T Cells and Phagocytes Provide Protection from Systemic Lupus ErythematosusAndrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, et al.
Journal of Computer-Aided Molecular Design|January 25, 2015
Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligandsStephanie N Lewis, Zulma Garcia, Raquel Hontecillas, et al.
Annual Review of Biomedical Data Science|April 16, 2025
The TITAN-X Platform Integrates Big Data, Artificial Intelligence, Bioinformatics, and Advanced Computational Modeling to Understand Immune Responses and Develop the Next Wave of Precision MedicinesRyan Baker, Josep Bassaganya-Riera, Nuria Tubau-Juni, et al.
Drug and Chemical Toxicology|October 26, 2019
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Journal of Medicinal Chemistry|December 10, 2016
An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel DiseaseAdria Carbo, Richard D Gandour, Raquel Hontecillas, et al.
Inflammatory Bowel Diseases|November 7, 2023
Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's DiseaseNuria Tubau-Juni, Raquel Hontecillas, Andrew J Leber, et al.
Inflammatory Bowel Diseases|July 12, 2023
Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 ActivationNuria Tubau-Juni, Josep Bassaganya-Riera, Andrew J Leber, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2019
Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4<sup>+</sup> T CellsAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Scientific Reports|October 7, 2021
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasisNuria Tubau-Juni, Raquel Hontecillas, Andrew Leber, et al.
Pageof 13

Showing results (41-50 of 124) with videos related to

Sort By:
Pageof 13
Journal of Molecular Modeling|June 1, 2010
Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeuticsPinyi Lu, David R Bevan, Stephanie N Lewis, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2024
Immunometabolic Mechanisms of LANCL2 in CD4+ T Cells and Phagocytes Provide Protection from Systemic Lupus ErythematosusAndrew Leber, Raquel Hontecillas, Nuria Tubau-Juni, et al.
Journal of Computer-Aided Molecular Design|January 25, 2015
Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligandsStephanie N Lewis, Zulma Garcia, Raquel Hontecillas, et al.
Annual Review of Biomedical Data Science|April 16, 2025
The TITAN-X Platform Integrates Big Data, Artificial Intelligence, Bioinformatics, and Advanced Computational Modeling to Understand Immune Responses and Develop the Next Wave of Precision MedicinesRyan Baker, Josep Bassaganya-Riera, Nuria Tubau-Juni, et al.
Drug and Chemical Toxicology|October 26, 2019
Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1Andrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Journal of Medicinal Chemistry|December 10, 2016
An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel DiseaseAdria Carbo, Richard D Gandour, Raquel Hontecillas, et al.
Inflammatory Bowel Diseases|November 7, 2023
Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's DiseaseNuria Tubau-Juni, Raquel Hontecillas, Andrew J Leber, et al.
Inflammatory Bowel Diseases|July 12, 2023
Oral Omilancor Treatment Ameliorates Clostridioides difficile Infection During IBD Through Novel Immunoregulatory Mechanisms Mediated by LANCL2 ActivationNuria Tubau-Juni, Josep Bassaganya-Riera, Andrew J Leber, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2019
Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4<sup>+</sup> T CellsAndrew Leber, Raquel Hontecillas, Victoria Zoccoli-Rodriguez, et al.
Scientific Reports|October 7, 2021
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasisNuria Tubau-Juni, Raquel Hontecillas, Andrew Leber, et al.
Pageof 13